Jitendar K Sharma¹, Umesh Gupta², Greeshma Gopalan³, Keerthan RM³ and Kavita Kachroo⁴*

¹MD & CEO/ ED, Kalam Institute of Health Technology, Andhra Pradesh Med Tech Zone, Visakhapatnam, India
²Professor, Head of Mats School of Business Studies, MATS Institute of Management and Entrepreneurship, Bangalore, India
³Scientist -A, Kalam Institute of Health Technology, Andhra Pradesh Med Tech Zone, Visakhapatnam, India ⁴Scientist -D, Kalam Institute of Health Technology, Andhra Pradesh Med Tech Zone, Visakhapatnam, India

*Corresponding Author: Kavita Kachroo, Scientist -D, Kalam Institute of Health Technology, Andhra Pradesh Med Tech Zone, Visakhapatnam, India.

Received: November 22, 2021; Published: December 29, 2021

Abstract

Introduction: Ever since the first case was reported in December, in China, Coronavirus disease 2019 (COVID-19) has spread over 218 countries and the casualty prediction of the third wave in India. Making it an absolute necessity for a rapid and accurate detection and diagnosis of the infection for prevention and containment of the disease. Molecular testing (RT-PCR) is considered to be the gold standard for COVID-19 diagnosis is considered accurate.

Methods: The primary COVID-19 diagnosis is done by Polymerase Chain Reaction (PCR) testing. The most common method used for identifying the genetic material from the SARS-CoV-2 is the real-time polymerase chain reaction RT-PCR. A decision analytical model was prepared for RT-PCR testing for COVID-19 diagnosis by selecting three Made in India diagnostic kits (RT-PCR-X, Y and Z) using Tree Age Pro software.

Results: From the economic evaluation, NMB (Net Monitory Benefit) for RT-PCR Y being ₹ 45,43,740 higher and is the most cost-effective intervention as it saves more money compared to other interventions per DALY averted.

Conclusion: Incremental cost-effectiveness ratio (ICER) was calculated, and it is identified that RT-PCR Y is cost effective at ₹ 850 per DALY averted.

PROSPERO ID: PROSPERO CRD42021237539.

Keywords: Cost-effectiveness; COVID-19; Real-time Polymerase Chain Reaction; RT-PCR Kits

References

1. Goudouris Ekaterini. “Laboratory Diagnosis of COVID-19”. Jornal de Pediatria 97 (2020).
2. “COVIDINDIA.ORG Open Testing Data - Google Sheets” (2021).
3. “WHO Coronavirus Disease (COVID-19) Dashboard” (2021).
4. “COVID-19 Diagnostics in Context”. Science Translational Medicine (2021).
5. Carter Linda J., et al. “Assay Techniques and Test Development for COVID-19 Diagnosis”. ACS Central Science5 (2020): 591-605.
6. Brooks Zoe and Saswati Das. “COVID-19 Testing – Impact of Prevalence, Sensitivity, and Specificity on Patient Risk and Cost”. American Journal of Clinical Pathology 5 (2020): 575-584.
7. Romero-Alvarez Daniel., et al. “<p>Cycle Threshold Values in the Context of Multiple RT-PCR Testing for SARS-CoV-2</P>“. Risk Management and Healthcare Policy 14 (2021): 1311-1317.
8. DeArmond Megan., et al. “Diagnostic Accuracy of Rapid Antigen Tests for COVID-19 Compared to the Viral Genetic Test in Adults: A Systematic Review Protocol”. JBI Evidence Synthesis5 (2021): 1148-1156.
9. “Coronavirus Disease 2019 Testing Basics”. FDA (2021).
10. Jo Min Woo., et al. “The Burden of Disease Due to COVID-19 in Korea Using Disability-Adjusted Life Years”. Journal of Korean Medical Science21 (2020): e199.
11. “Home - TreeAge Software” (2021).
12. Srinivisan R. “Health care in india-vision 2020 issues and prospects”.

Citation

Citation: Jitendar K Sharma., et al. “ Economic Analysis of Covid-19 Diagnostic Kits in India”. Acta Scientific Paediatrics 5.1 (2022): 02-08.

Copyright

Copyright: © 2022 Jitendar K Sharma., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.